NAFLD in lean individuals: not a benign disease
has served on the speakers bureau for Novo Nordisk and is a clinical investigator in several Novo Nordisk trials (e.g., Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes [SUSTAIN]-6, SUSTAIN-9, FLOW, Semaglutide Cardiovascular Outcomes Trial [SOUL], and CagriSema)
Simply apply gentle pressure with a clean cotton ball or gauze for a few seconds after injection if you notice any bleeding
For additional peace of mind, reviewing the medications prescribing information can offer valuable insights into proper usage, potential side effects, and safety precautions
Those differences trace back to molecular structure, which determines everything downstream
Early studies suggest that Tirzepatide might provide superior weight loss outcomes compared to GLP-1 agonists alone